lapatinib has been researched along with ldn 193189 in 2 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (ldn 193189) | Trials (ldn 193189) | Recent Studies (post-2010) (ldn 193189) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 113 | 0 | 106 |
| Protein | Taxonomy | lapatinib (IC50) | ldn 193189 (IC50) |
|---|---|---|---|
| Bone morphogenetic protein receptor type-1B | Homo sapiens (human) | 0.0245 | |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 0.4856 | |
| Bone morphogenetic protein 4 | Homo sapiens (human) | 0.0049 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.4314 | |
| Bone morphogenetic protein receptor type-1A | Homo sapiens (human) | 0.0124 | |
| Activin receptor type-1B | Homo sapiens (human) | 0.7218 | |
| TGF-beta receptor type-1 | Homo sapiens (human) | 0.431 | |
| Serine/threonine-protein kinase receptor R3 | Homo sapiens (human) | 0.0147 | |
| TGF-beta receptor type-2 | Homo sapiens (human) | 0.1482 | |
| Dual specificity protein kinase CLK2 | Homo sapiens (human) | 0.4856 | |
| 5'-AMP-activated protein kinase subunit gamma-1 | Homo sapiens (human) | 0.4856 | |
| Activin receptor type-1 | Homo sapiens (human) | 0.2081 | |
| Bone morphogenetic protein receptor type-2 | Homo sapiens (human) | 3.845 | |
| 5'-AMP-activated protein kinase subunit beta-1 | Homo sapiens (human) | 0.6129 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Bullock, AN; Canning, P; Choi, S; Cuny, GD; Mohedas, AH; Sanvitale, CE; Wang, Y; Xing, X; Yu, PB | 1 |
2 other study(ies) available for lapatinib and ldn 193189
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
Topics: Activin Receptors, Type I; Aminopyridines; Humans; Mutation; Myositis Ossificans; Phenols; Protein Kinase Inhibitors; Structure-Activity Relationship | 2014 |